Role of the Pharmacist in the Management of Polypharmacy and Drug
Interactions in the Elderly Patient with Chemotherapy

Silvania Maria   Saldanha   de Souza; José Cleberson   Santos   Soares; Iago Dillion   Lima   Cavalcanti
doi:10.2174/1573394719666230403110650
Abstract

Introduction: This study aimed to review the role of the pharmacist in cases of polypharmacy in the care of elderly patients with cancer.
Methods: An narrative literature review was carried out using the descriptors "Polypharmacy", "Pharmacological interactions", "Geriatrics" and "Antineoplastic agents", in the ScienceDirect, MEDLINE, and CAPLUS databases.
Results: One hundred and ten articles were identified, of which 82 were included in this review. The articles showed the importance of evaluating drug interactions in the treatment of cancer in oncogeriatric patients due to the high amount of drugs that these patients use, which can exceed 6 drugs per day, and that these interactions can compromise the treatment of the patient, as well as induce serious toxic effects, causing the patient to be hospitalized or even die.
Conclusion: The inclusion of the pharmacist in the care of oncogeriatric patients reduces the risk of interaction through pharmacotherapeutic monitoring.
Keywords: Polypharmacy, pharmacological interactions, geriatrics, antineoplastic agents, drug interactions, chemotherapy.
« Previous Next »
Graphical Abstract

[1]
Duarte MB, Rego MAV. Comorbidity between depression and clinical diseases in a geriatric outpatient clinic. Cad Saude Publica  2007; 23(3): 691-700.
 [http://dx.doi.org/10.1590/S0102-311X2007000300027] [PMID:  17334582]

[2]
Melgaço TB, Carrera J de S, do Nascimento DEB. Maia C do SF. Polypharmacy and occurrences of possible drug interactions. Rev Med  2011; 25(1)

[3]
Leal MCC, Marques APO, Marino JG, Austregésilo SC. Profile of nursing homes in the city of Recife, PE, Brazil. Rev Bras Geriatr Gerontol  2006; 9(3): 39-48.
 [http://dx.doi.org/10.1590/1809-9823.2006.09034]

[4]
Vespa J, Medina L, Armstrong DM. Demographic turning points for the United States: Population projections for 2020 to 2060 US Census Bur  2020; 1-15.

[5]
Extermann M. Measurement and impact of comorbidity in older cancer patients. Crit Rev Oncol Hematol  2000; 35(3): 181-200.
 [http://dx.doi.org/10.1016/S1040-8428(00)00090-1] [PMID:  10960800]

[6]
Satariano WA, Silliman RA. Comorbidity: Implications for research and practice in geriatric oncology. Crit Rev Oncol Hematol  2003; 48(2): 239-48.
 [http://dx.doi.org/10.1016/j.critrevonc.2003.08.002] [PMID:  14607386]

[7]
Stefanacci RG, Khan T. Can managed care manage polypharmacy? Clin Geriatr Med  2017; 33(2): 241-55.
 [http://dx.doi.org/10.1016/j.cger.2017.01.005] [PMID:  28364994]

[8]
Halli-Tierney AD, Scarbrough C, Carroll D. Polypharmacy: Evaluating risks and deprescribing. Am Fam Physician  2019; 100(1): 32-8.
 [PMID:  31259501]

[9]
Cavalcanti IDL. Plypharmacy in cancer therapy. Chemotherapy protocols and infusion sequence: Schedule considerations in cancer treatment. Cham: Springer 2022.
 [http://dx.doi.org/10.1007/978-3-031-10839-6_1]

[10]
Faria C de O, Reis CM, Santos AG, Reis AMM. Drug interactions in elderly cancer patients treated at a hematology-oncology outpatient clinic. Rev Bras Cancerol  2018; 64(1): 61-8.
 [http://dx.doi.org/10.32635/2176-9745.RBC.2018v64n1.119]

[11]
Baethge C, Goldbeck-Wood S, Mertens S. SANRA-a scale for the quality assessment of narrative review articles. Res Integr Peer Rev  2019; 4(1): 5.
 [http://dx.doi.org/10.1186/s41073-019-0064-8] [PMID:  30962953]

[12]
Borges GM. Health transition in Brazil: Regional variations and divergence/convergence in mortality. Cad Saude Publica  2017; 33(8): e00080316.
 [http://dx.doi.org/10.1590/0102-311x00080316] [PMID:  28832781]

[13]
Francisco PMSB, Friestino JKO, Ferraz R de O, Bacurau AG de M, Stopa SR, Filho D de CM. Prevalence of diagnosis and types of câncer in the elderly: Data from national health survey 2013. Rev Bras Geriatr Gerontol  2020; 23(2)
 [http://dx.doi.org/10.1590/1981-22562020023.200023]

[14]
(WHO). Chronic diseases. Available from:.  https://www.who.int/health-topics/noncommunicable-diseases#tab=tab_1 (Accessed November 13, 2020).

[15]
Silva NM, dos Santos MA, de Oliveira RAA, et al. Elderly undergoing chemotherapy: Relationship between stress level, depressive symptoms and hope. Psychol: Theory Res  2019; 35: e35441.

[16]
Beinse G, Reitter D, Segaux L, et al. Potential drug-drug interactions and risk of unplanned hospitalization in older patients with cancer: A survey of the prospective ELCAPA (ELderly CAncer PAtients) cohort. J Geriatr Oncol  2020; 11(4): 586-92.
 [http://dx.doi.org/10.1016/j.jgo.2019.07.023] [PMID:  31445850]

[17]
Marques GFM, Rezende DMRP, Silva IP, et al. Polypharmacy and potentially inappropriate medications for elder people in gerontological nursing. Rev Bras Enferm  2018; 71(5): 2440-6.
 [http://dx.doi.org/10.1590/0034-7167-2017-0211] [PMID:  30304174]

[18]
Pomatto LCD, Davies KJA. The role of declining adaptive homeostasis in ageing. J Physiol  2017; 595(24): 7275-309.
 [http://dx.doi.org/10.1113/JP275072] [PMID:  29028112]

[19]
Atamna H, Tenore A, Lui F, Dhahbi JM. Organ reserve, excess metabolic capacity, and aging. Biogerontology  2018; 19(2): 171-84.
 [http://dx.doi.org/10.1007/s10522-018-9746-8] [PMID:  29335816]

[20]
Singh JC, Lichtman SM. Effect of age on drug metabolism in women with breast cancer. Expert Opin Drug Metab Toxicol  2015; 11(5): 757-66.
 [http://dx.doi.org/10.1517/17425255.2015.1037277] [PMID:  25940027]

[21]
Fuentes E, Fuentes M, Alarcón M, Palomo I. Immune system dysfunction in the elderly  An Acad Bras Cienc  2017; 89(1)

[22]
Rougé Bugat ME, Bourgouin M, Gérard S, et al. Drug prescription including interactions with anticancer treatments in the elderly: A global approach. J Nutr Health Aging  2017; 21(8): 849-54.
 [http://dx.doi.org/10.1007/s12603-017-0946-8] [PMID:  28972235]

[23]
Teixeira AKS, Vasconcelos JLA. Histopathological profile of patients diagnosed with malignant tumors assisted in a hospital of reference of Agreste Pernambucano. J Bras Patol Med Lab  2019; 55(1): 87-97.
 [http://dx.doi.org/10.5935/1676-2444.20190002]

[24]
Mohile SG, Dale W, Somerfield MR, et al. Practical assessment and management of vulnerabilities in older patients receiving chemotherapy: ASCO guideline for geriatric oncology. J Clin Oncol  2018; 36(22): 2326-47.
 [http://dx.doi.org/10.1200/JCO.2018.78.8687] [PMID:  29782209]

[25]
Taberna M, Gil Moncayo F, Jané-Salas E, et al. The multidisciplinar team (MDT) approach and quality of care. Front Oncol  2020; 10: 85.
 [http://dx.doi.org/10.3389/fonc.2020.00085] [PMID:  32266126]

[26]
Schmidt H, Boese S, Lampe K, et al. Trans sectoral care of geriatric cancer patients based on comprehensive geriatric assessment and patient-reported quality of life - Results of a multicenter study to develop and pilot test a patient-centered interdisciplinary care concept for geriatric oncology patients (PIVOG). J Geriatr Oncol  2017; 8(4): 262-70.
 [http://dx.doi.org/10.1016/j.jgo.2017.04.002] [PMID:  28533106]

[27]
Cavalcanti I. Chemotherapy Protocols and Infusion Sequence: Schedule Considerations in Cancer Treatment. 2022.
 [http://dx.doi.org/10.1007/978-3-031-10839-6]

[28]
Jingwen B, Yaochen L, Guojun Z. Cell cycle regulation and anticancer drug discovery. Cancer Biol Med  2017; 14(4): 348-62.
 [http://dx.doi.org/10.20892/j.issn.2095-3941.2017.0033] [PMID:  29372101]

[29]
Cavalcanti I, Soares J. Conventional cancer treatment. Advances in Cancer Treatment 2021.
 [http://dx.doi.org/10.1007/978-3-030-68334-4_4]

[30]
Calixto-Lima L, Martins de Andrade E, Gomes AP, Geller M, Siqueira-Batista R. Dietetic management in gastrointestinal complications from antimalignant chemotherapy. Nutr Hosp  2012; 27(1): 65-75.
 [http://dx.doi.org/10.1590/S0212-16112012000100008] [PMID:  22566305]

[31]
Saponara M, Gatto L, Di Nunno V, et al. Successful treatment with personalized dosage of imatinib in elderly patients with gastrointestinal stromal tumors. Anticancer Drugs  2016; 27(4): 353-63.
 [http://dx.doi.org/10.1097/CAD.0000000000000331] [PMID:  26720290]

[32]
Stout NL, Sabo Wagner S. Antineoplastic therapy side effects and polypharmacy in older adults with cancer. Top Geriatr Rehabil  2019; 35(1): 15-30.
 [http://dx.doi.org/10.1097/TGR.0000000000000212] [PMID:  31011239]

[33]
Magalhaes LG, Ferreira LLG, Andricopulo AD. Recent advances and perspectives in cancer drug design. An Acad Bras Cienc  2018; 90(1) (Suppl. 2): 1233-50.

[34]
Delou JMA, Souza ASO, Souza LCM, Borges HL. Highlights in resistance mechanism pathways for combination therapy. Cells  2019; 8(9): 1013.
 [http://dx.doi.org/10.3390/cells8091013] [PMID:  31480389]

[35]
Rougé Bugat ME, Bréchemier D, Balardy L. Polypharmacy and potentially inappropriate medication use among senior adults with cancer: what is the best approach? J Clin Oncol  2015; 33(34): 4123-4.
 [http://dx.doi.org/10.1200/JCO.2015.62.8149] [PMID:  26351346]

[36]
Williams GR, Mackenzie A, Magnuson A, et al. Comorbidity in older adults with cancer. J Geriatr Oncol  2016; 7(4): 249-57.
 [http://dx.doi.org/10.1016/j.jgo.2015.12.002] [PMID:  26725537]

[37]
Mokhtari RB, Homayouni TS, Baluch N, et al. Combination therapy in combating cancer. Oncotarget  2017; 8(23): 38022-43.
 [http://dx.doi.org/10.18632/oncotarget.16723] [PMID:  28410237]

[38]
Bukowski K, Kciuk M, Kontek R. Mechanisms of multidrug resistance in cancer chemotherapy. Int J Mol Sci  2020; 21(9): 3233.
 [http://dx.doi.org/10.3390/ijms21093233] [PMID:  32370233]

[39]
Lees J, Chan A. Polypharmacy in elderly patients with cancer: Clinical implications and management. Lancet Oncol  2011; 12(13): 1249-57.
 [http://dx.doi.org/10.1016/S1470-2045(11)70040-7] [PMID:  21741307]

[40]
Aszalos A. P-Glycoprotein-based drug-drug interactions: Preclinical methods and relevance to clinical observations. Arch Pharm Res  2004; 27(2): 127-35.
 [http://dx.doi.org/10.1007/BF02980095] [PMID:  15022711]

[41]
Lonsdale DO, Baker EH. Understanding and managing medication in elderly people. Best Pract Res Clin Obstet Gynaecol  2013; 27(5): 767-88.
 [http://dx.doi.org/10.1016/j.bpobgyn.2013.06.002] [PMID:  23850054]

[42]
Aszalos A. Drug-drug interactions affected by the transporter protein, P-glycoprotein (ABCB1, MDR1). Drug Discov Today  2007; 12(19-20): 838-43.
 [http://dx.doi.org/10.1016/j.drudis.2007.07.021] [PMID:  17933685]

[43]
Del Re M, Fogli S, Derosa L, et al. The role of drug-drug interactions in prostate cancer treatment: Focus on abiraterone acetate/prednisone and enzalutamide. Cancer Treat Rev  2017; 55: 71-82.
 [http://dx.doi.org/10.1016/j.ctrv.2017.03.001] [PMID:  28340451]

[44]
Carcelero E, Anglada H, Tuset M, Creus N. Interactions between oral antineoplastic agents and concomitant medication: A systematic review. Expert Opin Drug Saf  2013; 12(3): 403-20.
 [http://dx.doi.org/10.1517/14740338.2013.784268] [PMID:  23586848]

[45]
MonteiroCR de ASchoueri JHM, Cardial DT, et al.  Evaluation of the systemic and therapeutic repercussions caused by drug interactions in oncology patients. Rev Assoc Med Bras  2019; 65(5): 611-7.

[46]
Thomas-Schoemann A, Blanchet B, Bardin C, et al. Drug interactions with solid tumour-targeted therapies. Crit Rev Oncol Hematol  2014; 89(1): 179-96.
 [http://dx.doi.org/10.1016/j.critrevonc.2013.08.007] [PMID:  24041628]

[47]
Dalton K, Byrne S. Role of the pharmacist in reducing healthcare costs: Current insights. Integr Pharm Res Pract  2017; 6: 37-46.
 [http://dx.doi.org/10.2147/IPRP.S108047] [PMID:  29354549]

[48]
Clairet AL, Boiteux-Jurain M, Curtit E, et al. Interaction between phytotherapy and oral anticancer agents: Prospective study and literature review. Med Oncol  2019; 36(5): 45.
 [http://dx.doi.org/10.1007/s12032-019-1267-z] [PMID:  30993543]

[49]
Domínguez-Alonso JA, Conde-Estévez D, Bosch D, Pi-Figueras M, Tusquets I. Breast cancer, placing drug interactions in the spotlight: Is polypharmacy the cause of everything? Clin Transl Oncol  2021; 23(1): 65-73.
 [http://dx.doi.org/10.1007/s12094-020-02386-8] [PMID:  32449126]

[50]
Balducci L, Goetz-Parten D, Steinman MA. Polypharmacy and the management of the older cancer patient. Ann Oncol  2013; 24 (Suppl. 7): vii36-40.
 [http://dx.doi.org/10.1093/annonc/mdt266] [PMID:  24001761]

[51]
de Boer AZ, Derks MGM, de Glas NA, et al. Metastatic breast cancer in older patients: A longitudinal assessment of geriatric outcomes. J Geriatr Oncol  2020; 11(6): 969-75.
 [http://dx.doi.org/10.1016/j.jgo.2020.04.002] [PMID:  32381437]

[52]
Pamoukdjian F, Aparicio T, Zelek L, et al. Impaired mobility, depressed mood, cognitive impairment and polypharmacy are independently associated with disability in older cancer outpatients: The prospective Physical Frailty in Elderly Cancer patients (PF-EC) cohort study. J Geriatr Oncol  2017; 8(3): 190-5.
 [http://dx.doi.org/10.1016/j.jgo.2017.02.003] [PMID:  28236586]

[53]
Götze H, Köhler N, Taubenheim S, Lordick F, Mehnert A. Polypharmacy, limited activity, fatigue and insomnia are the most frequent symptoms and impairments in older hematological cancer survivors (70+): Findings from a register-based study on physical and mental health. J Geriatr Oncol  2019; 10(1): 55-9.
 [http://dx.doi.org/10.1016/j.jgo.2018.05.011] [PMID:  29880406]

[54]
Festen S, van der Wal-Huisman H, van der Leest AHD, et al. The effect of treatment modifications by an onco-geriatric MDT on one-year mortality, days spent at home and postoperative complications. J Geriatr Oncol  2021; 12(5): 779-85.
 [http://dx.doi.org/10.1016/j.jgo.2020.12.003] [PMID:  33342722]

[55]
Gnjidic D, Le Couteur DG, Kouladjian L, Hilmer SN. Deprescribing trials: Methods to reduce polypharmacy and the impact on prescribing and clinical outcomes. Clin Geriatr Med  2012; 28(2): 237-53.
 [http://dx.doi.org/10.1016/j.cger.2012.01.006] [PMID:  22500541]

[56]
Qerem WA, Bashir Jarrar Y, Sheikh IA, ElMaadani A. The prevalence of drug-drug interactions and polypharmacy among elderly patients in Jordan. Biomed Res  2018; 29(12)
 [http://dx.doi.org/10.4066/biomedicalresearch.29-18-618]

[57]
Wang J, Shen JY, Yu F, et al. Medications associated with geriatric syndromes (MAGS) and hospitalization risk in home health care patients. J Am Med Dir Assoc  2022; 10: 1627-33.
 [http://dx.doi.org/10.1016/j.jamda.2022.03.012]

[58]
Kose E, Wakabayashi H, Yasuno N. Polypharmacy and malnutrition management of elderly perioperative patients with cancer: a systematic review. Nutrients  2021; 13(6): 1961.
 [http://dx.doi.org/10.3390/nu13061961] [PMID:  34200493]

[59]
Lu-Yao G, Nightingale G, Nikita N, et al. Relationship between polypharmacy and inpatient hospitalization among older adults with cancer treated with intravenous chemotherapy. J Geriatr Oncol  2020; 11(4): 579-85.
 [http://dx.doi.org/10.1016/j.jgo.2020.03.001] [PMID:  32199776]

[60]
Nightingale G, Pizzi LT, Barlow A, et al. The prevalence of major drug-drug interactions in older adults with cancer and the role of clinical decision support software. J Geriatr Oncol  2018; 9(5): 526-33.
 [http://dx.doi.org/10.1016/j.jgo.2018.02.001] [PMID:  29510896]

[61]
Outlaw D, Dai C, Al-Obaidi M, et al. The association of polypharmacy with functional status impairments, frailty, and health-related quality of life in older adults with gastrointestinal malignancy - Results from the Cancer and Aging Resilience Evaluation (CARE) registry. J Geriatr Oncol  2022; 13(5): 624-8.
 [http://dx.doi.org/10.1016/j.jgo.2021.12.010] [PMID:  34998720]

[62]
Ramsdale E, Lemelman T, Loh KP, et al. Geriatric assessment-driven polypharmacy discussions between oncologists, older patients, and their caregivers. J Geriatr Oncol  2018; 9(5): 534-9.
 [http://dx.doi.org/10.1016/j.jgo.2018.02.007] [PMID:  29530495]

[63]
Leger DY, Moreau S, Signol N, et al. Polypharmacy, potentially inappropriate medications and drug-drug interactions in geriatric patients with hematologic malignancy: Observational single-center study of 122 patients. J Geriatr Oncol  2018; 9(1): 60-7.
 [http://dx.doi.org/10.1016/j.jgo.2017.07.015] [PMID:  28851511]

[64]
Munir A, Huws A, Khan S, Sharaiha Y, Holt S, Khawaja S. Geriatric assessment tool application in treatment recommendations for older women with breast cancer. Breast  2022; 63: 101-7.
 [http://dx.doi.org/10.1016/j.breast.2022.03.012] [PMID:  35366503]

[65]
Hakozaki T, Matsuo T, Shimizu A, Ishihara Y, Hosomi Y. Polypharmacy among older advanced lung cancer patients taking EGFR tyrosine kinase inhibitors. J Geriatr Oncol  2021; 12(1): 64-71.
 [http://dx.doi.org/10.1016/j.jgo.2020.09.011] [PMID:  32952094]

[66]
Sugidono M, Lo M, Young R, et al. Impact of polypharmacy prior to allogeneic hematopoietic stem cell transplantation in older adults. Transplant Cell Ther  2021; 27(4): 344.e1-5.
 [http://dx.doi.org/10.1016/j.jtct.2021.01.001] [PMID:  33836888]

[67]
Prithviraj GK, Koroukian S, Margevicius S, Berger NA, Bagai R, Owusu C. Patient characteristics associated with polypharmacy and inappropriate prescribing of medications among older adults with cancer. J Geriatr Oncol  2012; 3(3): 228-37.
 [http://dx.doi.org/10.1016/j.jgo.2012.02.005] [PMID:  22712030]

[68]
Choukroun C, Leguelinel-Blache G, Roux-Marson C, et al. Impact of a pharmacist and geriatrician medication review on drug-related problems in older outpatients with cancer. J Geriatr Oncol  2021; 12(1): 57-63.
 [http://dx.doi.org/10.1016/j.jgo.2020.07.010] [PMID:  32800700]

[69]
Lattanzio F, Laino I, Pedone C, et al. Geriatric conditions and adverse drug reactions in elderly hospitalized patients. J Am Med Dir Assoc  2012; 13(2): 96-9.
 [http://dx.doi.org/10.1016/j.jamda.2011.04.006] [PMID:  21621472]

[70]
Jeon MS, Jeong YM, Yee J, et al. Association of pre-operative medication use with unplanned 30-day hospital readmission after surgery in oncology patients receiving comprehensive geriatric assessment. Am J Surg  2020; 219(6): 963-8.
 [http://dx.doi.org/10.1016/j.amjsurg.2019.06.020] [PMID:  31255260]

[71]
Sirois C, Turner JP, Hébert J. Health professionals’ perspectives regarding polypharmacy in older patients with cancer: A mixed-design exploratory study. J Geriatr Oncol  2021; 12(6): 881-7.
 [http://dx.doi.org/10.1016/j.jgo.2021.02.027] [PMID:  33750672]

[72]
Jørgensen TL, Herrstedt J. The influence of polypharmacy, potentially inappropriate medications, and drug interactions on treatment completion and prognosis in older patients with ovarian cancer. J Geriatr Oncol  2020; 11(4): 593-602.
 [http://dx.doi.org/10.1016/j.jgo.2019.12.005] [PMID:  31883969]

[73]
Ramasubbu SK, Mahato SK, Agnihotri A, Pasricha RK, Nath UK, Das B. Prevalence, severity, and nature of risk factors associated with drug-drug interactions in geriatric patients receiving cancer chemotherapy: A prospective study in a tertiary care teaching hospital. Cancer Treat Res Commun  2021; 26: 100277.
 [http://dx.doi.org/10.1016/j.ctarc.2020.100277] [PMID:  33348276]

[74]
Iurlo A, Ubertis A, Artuso S, et al. Comorbidities and polypharmacy impact on complete cytogenetic response in chronic myeloid leukaemia elderly patients. Eur J Intern Med  2014; 25(1): 63-6.
 [http://dx.doi.org/10.1016/j.ejim.2013.11.002] [PMID:  24309387]

[75]
Woopen H, Richter R, Ismaeel F, et al. The influence of polypharmacy on grade III/IV toxicity, prior discontinuation of chemotherapy and overall survival in ovarian cancer. Gynecol Oncol  2016; 140(3): 554-8.
 [http://dx.doi.org/10.1016/j.ygyno.2016.01.012] [PMID:  26790772]

[76]
Popa MA, Wallace KJ, Brunello A, Extermann M, Balducci L. Potential drug interactions and chemotoxicity in older patients with cancer receiving chemotherapy. J Geriatr Oncol  2014; 5(3): 307-14.
 [http://dx.doi.org/10.1016/j.jgo.2014.04.002] [PMID:  24821377]

[77]
Narjoux G, Clarenne J, Azzouz B, Zeller P, Slimano F, Bouché O. Nightmares and hallucinations with aprepitant and opium powder: A suspected drug-drug interaction. Br J Clin Pharmacol  2019; 85(2): 454-6.
 [http://dx.doi.org/10.1111/bcp.13810] [PMID:  30479035]

[78]
Varallo FR, Planeta CS, de Carvalho Mastroianni P. Effectiveness of pharmacovigilance: Multifaceted educational intervention related to the knowledge, skills and attitudes of multidisciplinary hospital staff. Clinics  2017; 72(1): 51-7.
 [http://dx.doi.org/10.6061/clinics/2017(01)09] [PMID:  28226033]

[79]
Caldas ALL, Sá SPC, Oliveira Filho VC. Perceptions of pharmaceutical services among elderly people on polymedication. Rev Bras Enferm  2020; 73(5): e20190305.
 [http://dx.doi.org/10.1590/0034-7167-2019-0305] [PMID:  32609218]

[80]
Anacleto TA, Perini E, Rosa MB, César CC. Medication errors and drug-dispensing systems in a hospital pharmacy. Clinics  2005; 60(4): 325-32.
 [http://dx.doi.org/10.1590/S1807-59322005000400011] [PMID:  16138240]

[81]
Melo DO, Castro LL. Pharmacist’s contribution to the promotion of access and rational use of essential medicines in SUS. Cien Saude Colet  2017; 22(1): 235-44.
 [http://dx.doi.org/10.1590/1413-81232017221.16202015] [PMID:  28076546]

[82]
Alibhai SMH, Jin R, Loucks A, et al. Beyond the black box of geriatric assessment: Understanding enhancements to care by the geriatric oncology clinic. J Geriatr Oncol  2018; 9(6): 679-82.
 [http://dx.doi.org/10.1016/j.jgo.2018.03.012] [PMID:  29631899]

[83]
Suh Y, Ah YM, Lee E, Lee JY. Association of inappropriate polypharmacy with emergency department visits in older patients receiving anti-neoplastic therapy: A population-based study. Support Care Cancer  2021; 29(6): 3025-34.
 [http://dx.doi.org/10.1007/s00520-020-05759-5] [PMID:  33037903]

[84]
Hernandez-Torres C, Korc-Grodzicki B, Hsu T. Models of clinical care delivery for geriatric oncology in Canada and the United States: A survey of geriatric oncology care providers. J Geriatr Oncol  2022; 13(4): 447-53.
 [http://dx.doi.org/10.1016/j.jgo.2022.01.004] [PMID:  35101363]

[85]
Goede V, Stauder R. Multidisciplinary care in the hematology clinic: Implementation of geriatric oncology. J Geriatr Oncol  2019; 10(3): 497-503.
 [http://dx.doi.org/10.1016/j.jgo.2018.09.003] [PMID:  30241779]

[86]
Giger AKW, Ditzel HM, Jørgensen TL, et al. Predictive value of geriatric oncology screening and geriatric assessment of older patients with cancer: A randomized clinical trial protocol (PROGNOSIS-RCT). J Geriatr Oncol  2022; 13(1): 116-23.
 [http://dx.doi.org/10.1016/j.jgo.2021.07.005] [PMID:  34362713]

[87]
Xue D, Li P, Chen TH, Shi Q, Wang XS. Utility of a patient-reported symptom and functioning assessment tool for geriatric oncology care in China. Value Health Reg Issues  2022; 29: 28-35.
 [http://dx.doi.org/10.1016/j.vhri.2021.08.001] [PMID:  34801883]

[88]
Kikuchi R, Broadwater G, Shelby R, et al. Detecting geriatric needs in older patients with breast cancer through use of a brief geriatric screening tool. J Geriatr Oncol  2019; 10(6): 968-72.
 [http://dx.doi.org/10.1016/j.jgo.2019.04.010] [PMID:  31005647]

[89]
van Walree IC, Scheepers ERM, van den Bos F, van Huis-Tanja LH, Emmelot-Vonk MH, Hamaker ME. Clinical judgment versus geriatric assessment for frailty in older patients with cancer. J Geriatr Oncol  2020; 11(7): 1138-44.
 [http://dx.doi.org/10.1016/j.jgo.2020.05.011] [PMID:  32576520]

[90]
McClennon J, Vonnes C, Dosal B, Reich RR, Mason TM, Extermann M. Integrating geriatric screening in the clinical setting: Recommendations for older adult oncology patients. J Geriatr Oncol  2021; 12(7): 1010-4.
 [http://dx.doi.org/10.1016/j.jgo.2021.03.015] [PMID:  33814340]

[91]
Canouï-Poitrine F, Martinez-Tapia C, Paillaud E, et al. Geriatric impairments were directly and indirectly associated with mortality in older patients with cancer: A structural equation analysis. J Clin Epidemiol  2022; 148: 17-26.
 [http://dx.doi.org/10.1016/j.jclinepi.2022.04.004] [PMID:  35398191]

[92]
Maas HAAM, Janssen-Heijnen MLG, Olde Rikkert MGM, Machteld Wymenga AN. Comprehensive geriatric assessment and its clinical impact in oncology. Eur J Cancer  2007; 43(15): 2161-9.
 [http://dx.doi.org/10.1016/j.ejca.2007.08.002] [PMID:  17855074]

[93]
Russo C, Terret C, Cropet C, Albrand G. Geriatric assessment in oncology: Moving the concept forward. The 20 years of experience of the Centre Léon Bérard geriatric oncology program. J Geriatr Oncol  2018; 9(6): 673-8.
 [http://dx.doi.org/10.1016/j.jgo.2018.05.008] [PMID:  29866469]

[94]
Ishii R, Ogawa T, Ohkoshi A, Nakanome A, Takahashi M, Katori Y. Use of the Geriatric-8 screening tool to predict prognosis and complications in older adults with head and neck cancer: A prospective, observational study. J Geriatr Oncol  2021; 12(7): 1039-43.
 [http://dx.doi.org/10.1016/j.jgo.2021.03.008] [PMID:  33757718]

[95]
Flood KL, Carroll MB, Le CV, Brown CJ. Polypharmacy in hospitalized older adult cancer patients: Experience from a prospective, observational study of an Oncology-Acute care for elders unit. Am J Geriatr Pharmacother  2009; 7(3): 151-8.
 [http://dx.doi.org/10.1016/j.amjopharm.2009.05.002] [PMID:  19616183]

[96]
Deliens C, Deliens G, Filleul O, et al. Drugs prescribed for patients hospitalized in a geriatric oncology unit: Potentially inappropriate medications and impact of a clinical pharmacist. J Geriatr Oncol  2016; 7(6): 463-70.
 [http://dx.doi.org/10.1016/j.jgo.2016.05.001] [PMID:  27238734]
Rights & Permissions Print Cite
Article Metrics
29
2
Journal Information
For Authors
For Editors
For Reviewers
Explore Articles
Open Access
Open Access Articles
For Visitors
DOI https://dx.doi.org/10.2174/1573394719666230403110650	Print ISSN 1573-3947
Publisher Name Bentham Science Publisher	Online ISSN 1875-6301
Current Cancer Therapy Reviews

Role of the Pharmacist in the Management of Polypharmacy and Drug Interactions in the Elderly Patient with Chemotherapy

Abstract

Graphical Abstract

Related Journals

Related Books

Related Articles
